Press Releases
02/11/2011
ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine
01/05/2011
ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
Latest News
11/23/2010
ImmunGene
Receives $244,479 Grant Under The Patient Protection And Affordable Care
Program For Its Anti-Cancer Technology
11/11/2010
ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in
BioWorld Today
Publications
Targeting IFN-alpha to B Cell Lymphoma by a Tumor-Specific Antibody Elicits
Potent Antitumor Activities
By Tzu-Hsuan Huang, Koteswara R. Chintalacharuvu, and Sherie L. Morrison
The Journal of Immunology, 2007, 179: 6881– 6888
Download
PDF
Targeted delivery of interferon-alpha via fusion to anti-CD20 results in
potent antitumor activity against B-cell lymphoma.
By Xuan C, Steward KK, Timmerman JM, Morrison SL.
Blood. 2010 Apr 8;115(14):2864-71
Download PDF